Drug
Gsk1322322 Initial Fit For Purpose
Gsk1322322 Initial Fit For Purpose: highest development phase Phase 1, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| GSK1322322 Initial fit for purpose tablets NCT01818011 | Phase 1 | Infections, Bacterial |
Latest
No recent events.
Follow Gsk1322322 Initial Fit For Purpose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.